The coverage policy relies on peer-reviewed literature and established guidelines to confirm the test’s efficacy in improving health outcomes. By setting these standards, Concert provides a framework that its network of client health plans can adopt, streamlining the reimbursement process for providers and patients. Several of these client plans have already implemented the policy.

Lishan Aklog, M.D., Chairman and CEO of Lucid Diagnostics, noted that the move signals a broader trend toward commercial accessibility for the test. The company continues to negotiate with insurers and benefit managers nationwide to expand coverage for the diagnostic, which targets patients suffering from chronic gastroesophageal reflux disease at risk for esophageal cancer.